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Abst ract
Background: Pathologists and informaticians are becoming increasingly interested in 
electronic clinical decision support for pathology, laboratory medicine and clinical diagnosis. 
Improved decision support may optimize laboratory test selection, improve test result 
interpretation and permit the extraction of enhanced diagnostic information from existing 
laboratory data. Nonetheless, the Àeld of pathology decision support is still developing. To 
facilitate the exchange of ideas and preliminary studies, we convened a symposium entitled: 
Pathology data integration and clinical decision support. Methods: The symposium was 
held at the Massachusetts General Hospital, on May 10, 2013. Participants were selected 
to represent diverse backgrounds and interests and were from nine different institutions in 
eight different states. Results: The day included 16 plenary talks and three panel discussions, 
together covering four broad areas. Summaries of each presentation are included in this 
manuscript. Conclusions: A number of recurrent themes emerged from the symposium. 
Among the most pervasive was the dichotomy between diagnostic data and diagnostic 
information, including the opportunities that laboratories may have to use electronic 
systems and algorithms to convert the data they generate into more useful information. 
Differences between human talents and computer abilities were described; welldesigned 
symbioses between humans and computers may ultimately optimize diagnosis. Another 
key theme related to the unique needs and challenges in providing decision support for 
genomics and other emerging diagnostic modalities. Finally, many talks relayed how the 
barriers to bringing decision support toward reality are primarily personnel, political, 
infrastructural and administrative challenges rather than technological limitations.
Key words: Clinical decision support, genomics, interpretive reporting, machine 
learning, test utilization
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INTRODUCTION
Pathologists and informaticians are becoming increasingly 
interested in the application of electronic clinical 
decision support to pathology and laboratory medicine. 
Application of decision support has great potential to 
optimize laboratory test selection, improve test result 
interpretation and permit the extraction of enhanced 
diagnostic information from existing laboratory data.[1-3] 
This may in turn help to transform laboratory medicine 
from primarily an observational field to one more 
centered on interpretation and definitive, comprehensive 
and precise diagnosis. Anatomic pathology has similar 
potential to enhance the diagnostic information it 
delivers.
This transformation of pathology may not only help 
reduce the waste or errors frequently associated with 
laboratory test selection and result interpretation,[1,4-7] 
but may also enable a previously unattainable level of 
diagnostic precision. Advances in laboratory automation, 
next generation sequencing, mass spectrometry and other 
emerging data acquisition modalities will surely enhance 
laboratory efficiency and diagnostic value. However, 
substantial improvements in the diagnostic value of 
laboratory tests will also likely result from more effective 
use and interpretation of data from traditional assays 
and existing technologies. Clinical decision support for 
test selection[1,8] and test result interpretation[9] may 
help to avoid unnecessary testing, ensure correct tests 
are ordered and avoid misinterpretation of test results. 
Moreover, application of statistical, computational and 
machine-learning techniques to clinical and laboratory 
data may reveal key patterns and insights that manual 
interpretation of the data could not.[2,3] In fact, many of 
the barriers to expanding the clinical application of next 
generation sequencing and other diagnostic modalities 
lie not in the data collection, but in the analysis and 
interpretation.[10]
Transforming the focus of pathology and laboratory 
medicine to more broadly emphasize data analysis and 
personalized diagnosis may also be of key importance 
in maintaining the relevance of the specialty and 
enhancing the value of laboratory testing. In particular, 
expanding use of automation is leading to an increased 
perception that certain routine laboratory services can 
be thought of as commodities with cost being the only 
real consideration.[11,12] A key strategy for overcoming 
such commoditization of laboratory services will be to 
understand that even if generation of certain laboratory 
data becomes routine, the process of extracting useful 
diagnostic information from this data will become 
increasingly complex.[13] Laboratories and pathology 
services could shift their primary focus from creating 
data to generating diagnostic, prognostic and therapeutic 
information.[1,9,13,14] Furthermore, particularly with 
increased emphasis on cost-containment and utilization 
management, compounded by an increase in the 
complexity of testing (such as genomic analyses), it will 
be increasingly important for laboratories to assist with 
test selection.[15,16] Computational data analysis and 
decision support systems will almost certainly be integral 
to this evolution in pathology and laboratory diagnosis.[1,8]
Nonetheless, pathology decision support is still in 
its infancy. To facilitate the exchange of ideas and 
preliminary studies, we convened a symposium entitled: 
Pathology data integration and clinical decision support. 
Here we summarize some of the views shared in the 
symposium to provide an overview of the current state of 
the field and the challenges it faces.
METHODS/MEETING ORGANIZATION AND 
STRUCTURE
The symposium on Pathology data integration and 
clinical decision support, held at the Massachusetts 
General Hospital (MGH), Boston, MA on May 10, 2013, 
was sponsored by the MGH Department of Pathology 
and the Partners Fellowship Program in Pathology 
Informatics and was organized by JB, AD and JG. The 
speakers were selected to provide varied interests and 
backgrounds with half of the speakers coming from 
within the MGH Department of Pathology and half 
from institutions around the country. The 1-day meeting 
was divided into four subtopics and included 16 plenary 
talks, ranging from 20 to 25 min. The symposium also 
included three panel discussions during which questions 
from the audience were answered and discussed. This 
paper provides a brief summary of each plenary talk. In 
addition, the paper concludes with a synthesis of the key 
themes of the symposium and provides some “next-steps” 
for the field based upon the symposium presentations 
and discussions.
RESULTS
Block 1 Presentations: Big Picture Concepts and 
the Need for Pathology Data Integration and 
Decision Suppor t
David Louis, MD
The first talk of the day was by David Louis, 
Pathologist-in-Chief of the MGH Department of 
Pathology and Benjamin Castleman Professor of 
Pathology at Harvard Medical School. Dr. Louis’ talk, 
“The Skeleton of Computational Pathology,” described 
a vision for the future of pathology along with a 
“skeleton” of the “computational pathology” efforts 
ongoing within the MGH Department of Pathology. In 
particular, Dr. Louis first noted that laboratories and 
pathologists currently provide clinicians mostly with 
relatively discrete elements of diagnostic data, including 
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anatomic pathology interpretations, laboratory results 
and increasingly, “omics” data. Clinicians then must 
interpret this pathology data in the context of the 
clinical findings and medical knowledge to arrive at a 
diagnosis or treatment plan. However, moving forward, 
pathology services may add value by integrating within a 
single synthesized report an interpretation of the various 
elements of data they produce. The integrated report will 
interpret findings and results within the context of the 
particular clinical setting, utilizing medical knowledge 
derived from databases and medical literature.
Dr. Louis outlined an approach for reaching this goal and 
the final product may involve a pipeline containing at least 
six components: Clinical data integration, mathematical 
biologic modeling, clinical decision support, “omics and 
imaging” (algorithmically processing high complexity 
datasets), integrated reporting and performance analysis. 
In this pipeline, clinical data integration serves as the input 
step, integrated reporting is the output step and clinical 
decision support, mathematical modeling and “omics” and 
imaging comprise the “stuff in the middle,” processing, 
integrating and interpreting the data. Performance analysis 
will be used to monitor the entire process to identify areas 
for improvement, analyze findings in the context of health 
care resource utilization and demonstrate the clinical and 
economic value of the approach.
Dr. Louis further described the efforts ongoing within 
the MGH Department of Pathology to make this vision a 
reality. The department has organized six working groups 
corresponding to the six components noted above with 
over 80 members of the pathology department (faculty 
and trainees) participating in at least one working group. 
At the current time, the groups are carrying out analyses 
and designing projects in their assigned area. A steering 
committee that includes the chairpersons of each working 
group meets periodically to coordinate and integrate the 
work and activities across all six groups. Department-wide 
meetings in computational pathology occur about every 
6 months and are intended to update the faculty and 
trainees, to get further input from members of all working 
groups and to encourage other faculty and trainees to 
join the overall effort.
Brian Jackson, MD
Following Dr. Louis’ talk emphasizing the “what,” 
Brian Jackson, Chief Medical Informatics Officer 
at ARUP Laboratories and Associate Professor of 
Pathology (Clinical) at the University of Utah helped 
to elucidate the “why.” His talk, “The Psychology of 
Decision Making: W hy Don’t Those Darned Doctors Use 
Our Tests Properly?” introduced two important ideas:
1. The human brain is ineffective at deriving 
information from multidimensional data (i.e., many 
discrete elements such as with a set of many 
laboratory values from the same patient).
2. The brain is poor at “meta-cognition” and people 
often do not have accurate insight into why they 
make certain decisions. Similarly, the confidence 
that people place in the decisions or predictions they 
make may be impacted by factors not particularly 
relevant to the decision.
To illustrate these ideas, Dr. Jackson presented 
several studies. One small study,[17] first surveyed two 
rheumatologists to discover which factors they each 
considered most important in assessing disease activity 
in rheumatoid arthritis patients. The rheumatologists 
were then asked to assess disease activity in a set of 
patients based upon chart review. The study found that 
the rheumatologists thought that they were putting 
significant weight on all five of the factors surveyed when 
making their assessments. However, in practice, each 
rheumatologist based the assessments almost entirely on 
a single factor. Dr. Jackson noted that, to the extent that 
this small study is generalizable, the results illustrate that 
the physicians may make medical decisions without really 
understanding the basis for these decisions.
Dr. Jackson next presented a study of “horserace 
handicappers” who attempt to predict the outcomes 
of horse races by using various known “predictors.”[18] 
This study demonstrated that as the handicappers were 
presented with an increasing number of discrete data 
elements on which to make predictions (from 5-10 
to 20-40) the accuracy of their predictions remained 
unchanged, but the confidence in their predictions 
increased. To the extent that this horserace study can be 
extended to clinical diagnosis, Dr. Jackson concluded that 
“flooding doctors with data does not improve diagnostic 
accuracy, but it probably contributes to overconfidence.”
At the conclusion of his talk and during a panel 
discussion, Dr. Jackson considered the questions of 
where the “bottlenecks” are occurring in laboratory-based 
diagnosis. In particular, Dr. Jackson argued that we 
produce more data than we can currently use; we need 
to shift some of our emphasis away from increasing the 
availability of new data and toward better applying and 
extracting information from the data we already produce.
John Gilbertson, MD
John Gilbertson, Associate Chief for Informatics in the 
Department of Pathology at the MGH and Associate 
Professor at Harvard Medical School, presented 
“Pathology decisions and decision support.” In this talk, 
he described some of the technical and administrative 
limitations that will need to be overcome to provide 
the next generation of decision support and some 
solutions currently in progress. Among these challenges 
is that laboratory information systems (LIS) traditionally 
emphasize the technical aspects of the laboratory while 
providing comparatively little support for professional or 
interpretive activities. For example, whereas current LIS 
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systems support aspects ranging from specimen tracking 
to test or special stain ordering to billing, these systems 
often provide little more than a word processor for 
pathologists to generate interpretive reports. Likewise, 
clinical pathology systems often have relatively limited 
calculation functionality, significantly hindering the 
ability to implement advanced interpretive algorithms. 
Molecular LIS modules tend to be particularly limited 
with regard to support of professional interpretation.
Dr. Gilbertson proposed that LIS vendors supplement 
their traditional “technical LIS” systems by adding to 
them “professional LIS systems” with expanded capacity 
to facilitate pathologists’ decision making, accurate and 
efficient sign out and advanced interpretive algorithms. 
With regard to the latter, certain functions may not need 
to be directly within the main LIS, but could exist in 
external systems; nonetheless, LIS vendors would need 
to generate highly flexible application programming 
interfaces to enable such external functionality.
Other needs as pathology related clinical decision support 
advances include systems for advanced analytics, robust 
electronic health records (EHRs), structured, high quality 
data, pipelines for molecular and genomic pathology 
and infrastructures for data extraction, warehousing 
and computation. Tissue registries and digital pathology 
systems are other factors that may support various aspects 
of research and decision support. A final and perhaps most 
significant need are personnel with the skills, knowledge 
and desire to advance pathology decision support. This 
includes not only highly trained and skilled pathology 
informaticians, but also non-informatician pathologists 
with informatics literacy. Information technology (IT) and 
technical staff with these skills and interests are essential.
Solutions to many of the challenges are being currently 
considered in the computational pathology initiative 
within the MGH Department of Pathology (see 
description of the presentation by David Louis 
for additional detail). Other strategies include the 
development of informatics faculty consisting primarily of 
practicing pathologists (or researchers) with a secondary 
practice in informatics and the creation of a large and 
robust pathology informatics fellowship training program 
to address the personnel needs. MGH pathology is 
involved in a co-development agreement with Sunquest 
Information Systems to help develop a more advanced 
LIS; Dr. Gilbertson is working with Sunquest to expand 
the professional LIS functionality of the system.
Stephen BlackSchaffer, MD
Stephen Black-Schaffer, Associate Chief for Education 
and Training in the Department of Pathology at the 
MGH and Associate Professor of Pathology at Harvard 
Medical School, presented the final talk of the first block: 
“Clinical decision support: Implications for Pathology 
Performance Assessment and Trainee Education.” In this 
talk, he addressed how Pathology Departments can use 
the comprehensive clinical data they produce to assess 
the performance of both the operation as a whole and of 
individual pathologists, including trainees. Operational 
performance assessment is fundamentally quite similar to 
pathologist performance assessment and can use much of 
the same data.
In particular, Dr. Black-Schaffer conveyed the perception 
that Pathology Departments and Hospitals will increasingly 
need to assess and improve operational performance given 
increased emphasis on cost containment and shifting 
reimbursement models favoring efficiency. “Leakage” 
must be avoided. Dr. Black-Schaffer provided an example 
of how pathology and laboratory test performance can be 
analyzed to optimize the use of molecular testing on fine 
needle aspiration specimens taken from thyroid nodules.
Dr. Black-Schaffer also described how the data in the LIS 
could be used for performance assessment. In particular, 
resident sign-out could be compared with final attending 
review to objectively assess how well trainees are meeting 
key educational milestones and competencies. However, 
to do this in an automated fashion, LIS systems will have 
to store preliminary interpretations provided by trainees, 
in addition to final reports, in a structured form. A similar 
approach could also be used to evaluate peer-review of 
pathologist competency.
Block 2 Presentations: Clinical Decision Suppor t 
fo r  Resou r ce Ut ilizat ion  an d  Pion eer in g 
Diagnostic Modalities Including Genomics and 
Systems BiologyBased Models
Raskesh Nagarajan, MD, PhD
Rakesh Nagarajan, Associate Professor, Pathology and 
Immunology and Associate Professor, Genetics at 
Washington University School of Medicine, delivered 
the first talk of the second block: “Clinical Genomicist 
Workstation: Analyze, interpret and report Nextgen 
based molecular diagnostic studies.” He began this talk 
by noting the challenges involved in converting genomic 
sequencing data into actionable information. Most of 
the talk was devoted to describing a platform developed 
and used at Washington University in St. Louis to help 
overcome some of these challenges. This platform, the 
“Clinical Genomicist Workstation,” helps transform raw 
sequence data into an interpretive report by processing 
data in several tiers. The first tier is “seamless” from 
the perspective of the clinical genomicist and automates 
basic data processing such as sequencing alignment and 
variant calling. Given the clinical application of this 
system, this first tier tracks key information that may be 
critical to future re-evaluation such as the version of tools 
used and parameters specified.
W hereas the first tier focuses on identifying and 
calling genomic variants, the second tier begins to 
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ascribe meaning to these variants. It applies data from 
various genomic databases and knowledge repositories 
to identify the subset of variants with known clinical 
significance (and which are relevant to the case at hand). 
It also provides phenotypic information for these relevant 
variants. This step helps to reduce the number of variants 
the clinical genomicist must review from an overwhelming 
number to a more manageable number and conveniently 
provides clinical knowledge about the variants of known 
significance. The genomicist workstation also provides 
tools for automated clinical report generation and data 
visualization.
W hile tiers one and two involve processing data for 
individual patients, the third tier serves to curate the 
knowledge repository and the rules that can be used to 
assign clinical significance to variants. The knowledge 
curated in this tier helps to determine which variants 
are displayed to the clinical genomicist and under 
which circumstances. For example, selection of variants 
to display may be tailored to the patient’s test genomic 
test order (panel), phenotype, disease or medication list. 
Dr. Nagarajan also provided some planned or potential 
future enhancements for the system, including sharing of 
tier 3 knowledge repositories and rules across institutions.
John Higgins, MD
John Higgins, Assistant Pathologist in the Department 
of Pathology at MGH and Assistant Professor in the 
Department of Systems Biology at Harvard Medical 
School, delivered a talk entitled, “Systems Biology 
in Clinical Medicine: Mathematical Model-Based 
Diagnosis.” In it, Dr. Higgins argued against the view 
held by some that as available data becomes more 
expansive, traditional hypothesis-driven mechanistic 
biologic and clinical research will become obsolete and 
will be replaced by data mining. He suggested to the 
contrary that models may be necessary to help make 
sense of the data. W hile statistical data mining routines 
by themselves are prone to overfitting and may make 
differentiating “signal from noise” difficult, placing data 
in the context of mechanistic physiologic models helps 
constrain the set of hypotheses from that which a raw 
statistical approach might use and make true “signal” 
easier to identify. Likewise, Dr. Higgins argued that 
traditional human clinical intuition alone is inadequate 
for optimal interpretation of the large datasets that are 
now being developed, because “human intuition doesn’t 
scale to multidimensional data” but “human subjective 
bias does.”
Dr. Higgins went on to define and describe systems 
biology as “the formulation and analysis of mechanistic 
models of systems of interacting biological components.” 
Models need to be of appropriate detail and complexity 
to capture essential patterns, inputs and associations 
without being so complex as to be impractical to fit 
and compute and useless for helping us understand how 
the biological systems actually work. After discussing 
the importance of models, he devoted much of the talk 
to providing a specific example of a systems biology 
model of the lifecycle of circulating red blood cells 
that was derived and validated with existing clinical 
laboratory data. The model relies on single-red blood 
cell measurements routinely collected on a hematology 
analyzer and enables the inference of rates of blood cell 
maturation and clearance in the peripheral circulation. 
The model allows us to infer and quantify aspects of 
pathophysiology that cannot be measured directly and 
this additional information may enable earlier and more 
accurate diagnosis of conditions such as iron deficiency 
anemia. This model, described elsewhere in detail,[19] 
provides an important example, illustrating how through 
substantive modeling, we can extract substantially 
enhanced information from the data we already generate.
Dr. Higgins concluded his talk with a quote from Nobel 
Laureate, Sydney Brenner that captured many of the 
arguments from the talk: “The orgy of fact extraction 
in which everybody is currently engaged has, like most 
consumer economies, accumulated a vast debt. This is a 
debt of theory and some of us are soon going to have an 
exciting time paying it back-with interest, I hope.”[20]
Long Phi Le, MD, PhD
Dr. Long Le, Assistant in Pathology in the Department 
of Pathology at the MGH and Assistant Professor of 
Pathology at Harvard Medical School, described, in 
his talk, “Decision Support for Clinical Genomics,” 
the approach that the MGH is taking to develop a 
platform for tumor genotyping by next generation 
sequencing. Dr. Le argued that tumor therapeutics will 
be increasingly targeted to the individual mutational 
profile of the patient’s tumor. Like many of the genomics 
related talks, Dr. Le’s talk described the shift from the 
targeted detection of medically actionable mutations 
of known significance to next generation sequencing, a 
technique that will lead to the detection of many novel 
or rare variants with unknown diagnostic, prognostic and 
therapeutic implications.
The current tumor sequencing goal at MGH encompasses 
“> 1000 genes (~ 3.6 Mb), × 100 minimum coverage 
10 bp into introns, 6-8 Gb of data/tumor-normal pair, 
5-10% analytical sensitivity (with regard to tumor 
cellularity) and 3-4 week turnaround time.” To help 
reach this goal Dr. Le et al. have developed their own 
molecular laboratory information management system 
termed “Center for Integrated Diagnostics, Wiki, 
Laboratory Information Management System”. Based 
on the Semantic Mediawiki semantic web technology, 
this system supports computerized provider order 
entry (CPOE) to allow clinicians to directly input 
orders, a key to achieving an effective upfront workflow 
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and optimal, accurate test selection in the molecular 
diagnostics laboratory. It also supports the full breadth 
of the molecular laboratory internal workflow, including 
asset tracking (e.g. slides, blocks, nucleic acid extractions 
and reagents), slide labeling, assay worksheets, resulting, 
reporting, case tracking and document management. 
The system is “semi-integrated” with the main anatomic 
pathology LIS and has full query functionality of the 
stored structured data. Its scalability and capability 
for deployment outside of MGH is currently under 
investigation. Work to integrate a sequence interpretation 
pipeline into this setup is underway with collaboration 
from Dr. Gad Getz.
Finally, Dr. Le described a possible variant categorization 
scheme for NGS cancer genotyping reporting. Based on 
available evidence, variants with actionable treatment 
would be classified in the therapeutic category and further 
differentiated as “consensus” (based on documented 
standard of care consensus guidelines from the Food 
and Drug Administration [FDA], College of American 
Pathologists, or National Comprehensive Cancer Network) 
or “emerging” (based on availability of experimental 
drugs reported to be effective in late trials, early trials, 
case reports, or preclinical studies). Two other categories 
of action ability include “diagnostic” and “prognostic” 
markers with strong evidence from the literature. Variants 
which do not fall into the above categories but have some 
association with cancer pathogenesis would be reported 
under mutations with “other relevance.” Finally variants 
of clear unknown significance would be grouped by their 
functional pathways and reported at the end. Currently, 
the laboratory’s Semantic Mediawiki information 
management system is being expanded to support the 
curation of the variants and also structured reporting for 
the MGH cancer genotyping assay.
Brian Shirts, MD, PhD
Brian Shirts, Assistant Professor in the Department of 
Laboratory Medicine at the University of Washington, 
offered a complementary perspective on the challenges 
of providing decision support for genomic testing in his 
talk: “Complexity, Uncertainty and Constant Change: 
Decision Support for Clinical Next-Gen Sequencing.” 
Dr. Shirts began by highlighting an ironic tendency in 
laboratory testing: The more stable that a raw laboratory 
results is for an individual patient over time, the less 
likely it is that the general interpretation guidelines for 
that analyte will remain stable. For example, electrolytes 
can change rapidly and thus remain relevant for only a 
short period of time, but the interpretation guidelines 
for electrolytes have remained constant for decades. By 
contrast, germline genomic data will not change much 
over a patient’s life; however, given the rapidly evolving 
state of medical knowledge, the interpretation of a 
genetic variant may only remain current for a relatively 
short period of time. This irony highlights one of the 
key challenges in genomic testing: Data may need to be 
reinterpreted regularly throughout a patient’s life. The 
current processes, infrastructure and systems used in 
clinical and laboratory diagnosis are not well-adapted to 
a future where, even in the absence of new patient data 
or clinical changes, a laboratory result may require regular 
reinterpretation.
Dr. Shirts noted that the current practice in genomic 
data interpretation involves substantial non-automated 
interpretation. Genetic counselors are highly valuable in 
this regard and can “pay for themselves” by promoting 
appropriate and cost effective test utilization. In fact, 
a study from ARUP Laboratories demonstrated a very 
substantial cost saving attributable to genetic counselors 
actively managing genetic test ordering.
Moving forward, the desire will increasingly be to develop 
algorithmic and computational approaches to facilitate 
the interpretation and application of genomic data. 
However, there are inherent statistical limitations that may 
prevent automated genetic informatics implementation. 
Dr. Shirts used the example of partitioning test reference 
ranges based upon genomic information, with a strategy 
for doing this previously described in detail,[21] to 
illustrate one situation where limitations to integration 
of genomic and clinical information can be clearly 
illustrated. Another challenge is that many variants are 
rare, occurring in only a small portion of the population. 
It may be very difficult to determine the significance of 
these rare variants, even when they have large effects, due 
to the statistical limitations similar to those associated 
with finding patterns in multidimensional data when 
only a small number of data points are available (see 
discussion of overfitting in the talk by Jason Baron).
The field of genomic testing needs automated platforms 
for genomic data that integrate structured clinical 
data with genomic data that allow for facilitation of 
correlation and interpretation. Dr. Shirts stated that 
“personalized medicine is about the relationship between 
signal and noise,” and it is important for pathologists 
to help develop systems that filter the signal (clinically 
actionable data) from the noise (inter-individual genetic 
variability of no clinical significance).
Craig Mermel, MD, PhD
Craig Mermel, a resident in Clinical Pathology at the 
MGH with extensive experience in cancer genomics 
research, described some of the infrastructural challenges 
that will need to be addressed to facilitate routine 
tumor genotyping by next generation sequencing at the 
whole-exome or whole-genome levels. In delivering his 
talk, “Infrastructure and Reporting Challenges to Clinical 
Next-Generation Sequencing Programs,” Dr. Mermel drew 
upon and contrasted his experience in tumor genomics at 
the Broad Institute, to his experience helping to establish a 
next generation sequencing pipeline in the clinical setting.
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In evaluating some of the infrastructure challenges, 
Dr. Mermel argued that we need to be aware of several 
trends. First, sequencing capacity is expanding much 
more rapidly than computational capacity. Sequencing 
costs have declined by more than four orders of 
magnitude over the past decade to <  10 cents/megabase, 
while computational capacity follows roughly “Moore’s 
Law” doubling only about every 18-24 months. Currently, 
the bottleneck in many aspects of sequence analysis 
is computation and the imbalance between ability 
to produce sequence data and ability to analyze it is 
likely to further exacerbate moving forward. Paralleling 
this expansion of sequencing capacity, the number 
and types of sequencing platforms is expanding and 
shifting (Available from: http://www.omicsmaps.com 
for more up to date information) and new algorithmic 
techniques are rapidly being developed. Finally, the 
knowledge base is rapidly expanding; new mutations of 
functional significance are curated every day.
While all these aforementioned trends challenge both 
research and clinical applications of genomic sequencing, 
clinical applications have some additional considerations 
that must be addressed. These include requirements to 
comply with complex regulations (e.g. Health Insurance 
Portability and Accountability Act (HIPAA), Health 
Information Technology for Economic and Clinical 
Health Act (HITECH), Clinical Laboratory Improvement 
Amendments (CLIA), FDA), to interface with clinical 
information systems and workflows, to meet clinical 
standards with regard to information system stability, 
validity and consistency and to provide clinically acceptable 
turn-around times.
W hile the field has not solved all of these challenges, 
several developments may be inevitable. Foremost, 
most of the analysis will need to be automated; manual 
evaluation of variants beyond a final report would be 
prohibitively expensive. In fact, Dr. Mermel estimated that 
a single whole exome sequence would on average have 
approximately 500 novel variants, costing at least $2,000 
in pathologist time to review (assuming each variant could 
be reviewed in 1 min). In addition, it is not feasible for 
all institutions and research environments to develop 
their own analysis tools. We will need to work together as 
community to share tools and even analysis platforms.
Finally, Dr. Mermel argued that we should strongly 
consider using cloud architecture for our main sequence 
analysis needs. Among the advantages of the “cloud” are 
that rather than needing computer clusters capable of 
meeting peak needs and thus often leaving excess, unused 
capacity, cloud computing more efficiently distributes 
computing resources and only requires institutions to pay 
for the computing used. In addition, cloud architectures 
are potentially more nimble and adaptable to shifting 
analysis tools. Cloud based platforms may also facilitate 
inter-institutional collaboration, including sharing of 
analytic pipelines.
Alexis Carter, MD
Alexis Carter, Director of Pathology Informatics and 
Assistant Professor in the Department of Pathology and 
Laboratory Medicine and Department of Biomedical 
Informatics at Emory University School of Medicine, 
offered insight on transfusion clinical decision support. 
In her talk, “transfusion guidelines versus practice: The 
impact of clinical decision support tools on transfusion 
behavior,” she described work that she and colleagues did 
at Emory to improve the utilization of blood products. 
Blood products are commonly misused, most often in 
the direction of transfusing a patient when not indicated. 
At the very least, this puts patients at risk for harm 
while engendering unnecessary cost for the institution. 
Dr. Carter et al. undertook an effort to understand why 
physicians transfuse patients in an ethnographic study 
and this is being followed by a study looking at decision 
support systems in the EHR that will help encourage 
physicians to transfuse according to national[22-24] and 
institutional guidelines. Dr. Carter devoted the majority 
or her talk to discussing their specific findings which are 
unpublished data. Therefore, these findings are reserved 
for subsequent publication.
Block 3 Presentations: Technical Strategies and 
Methods for Implementing Data Integration and 
Decision Suppor t
Ulysses Balis, MD
Ulysses Balis, Associate Professor and Informatics 
Director in the Division of Pathology Informatics in the 
Department of Pathology in the University of Michigan 
Health System, introduced the emerging area of 
multi-analyte assays with algorithmic analysis (MAAAs), 
in his talk, “Machine-learning-based thiopurine 
monitoring and decision support as an exemplar of 
encoded data use in clinical settings.”
MAAAs work by applying machine learning or other 
algorithms to a panel of individual laboratory test results 
from a patient to generate diagnostic information that 
the individual results, interpreted in isolation, could 
not provide. Among the reasons why MAAAs may be 
useful is that the human brain is limited in its ability to 
discern complex patterns from high-dimensional data, 
such as a panel of results (see description of the talk by 
Brian Jackson). In contrast, however, these patterns may 
be discernable to computers using machine learning 
algorithms. Two widely known examples of MAAAs 
include liver fibrosis algorithms[25] and tests for fetal 
abnormalities (e.g., the “quad screen”.)
Dr. Balis devoted a substantial portion of his talk to 
describing a particular MAAA developed by colleagues 
at the University of Michigan to monitor therapy with 
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thiopurine medications. Thiopurines, commonly used 
to treat inflammatory bowel disease, require monitoring 
because they have narrow therapeutic indices and not all 
patients respond. Metabolite levels are sometimes assayed 
to for use in monitoring but this metabolite testing 
is expensive and not optimally predictive of response. 
A MAAA developed at the University of Michigan used a 
random forest classifier (an established machine learning 
technique) to predict patients’ thiopurine responses 
based upon a panel of routine hematology and chemistry 
analytes. Not only is this MAAA much less expensive, 
but actually more accurate in monitoring response, as 
compared to the metabolite test. This MAAA has been 
described in detail in Waljee et al., 2010.[26]
One challenge to implementing MAAAs and related 
approaches is that traditional LISs are incapable 
of executing the complex algorithms needed to 
integrate the individual results. The thiopurine MAAA 
was implemented using an external, distributed 
architecture (the LIDDEx System) interfacing with, but 
existing outside the LIS. However, to optimally apply 
such approaches going forward, LIS vendors will need 
to improve their systems’ functionality to facilitate 
data extraction and interaction with external systems 
and improve their ability to implement advanced data 
processing algorithms.
Jason Baron, MD
Jason Baron, Assistant in Pathology at the MGH and 
Instructor of Pathology at Harvard Medical School, 
presented “Pathology Decision Support Meets Big Data.” 
In this talk, he discussed emerging opportunities to 
identify novel patterns in clinical and laboratory data that 
may enhance decision support and increase the diagnostic 
information generated through laboratory testing. He also 
noted many of the accompanying challenges.
Dr. Baron began by explaining that in many cases, 
groups of patients exhibit wide variability in responses 
to treatment or ultimate outcomes, despite presenting 
similarly in terms of diagnoses, comorbidities and 
other currently known predictors of clinical course. 
His hypothesis is that by mining large sets of clinical 
and laboratory data, we may be able to identify subtle 
patterns that can predict prognosis, response to therapy 
or ideal clinical management in ways that standard 
manual interpretation of data cannot. Among the 
philosophical rationales Dr. Baron provided for this 
hypothesis is the reality that the human brain is incapable 
of optimally analyzing high-dimensionality data, leaving 
many “unexplored” opportunities for refinement in 
diagnosis. However, perhaps even more significant is that 
identification of subtle patterns requires large sets of 
data (see discussion of overfitting below) and even the 
busiest clinicians can only see a relatively small number 
of patients during the course of their careers. In contrast, 
a computer can “learn” from mining millions of patient 
records from a large health system or inter-institutional 
data sharing program.
After noting that large data sets will be necessary 
to identify complex patterns, Dr. Baron devoted the 
majority of his talk to answering the question, “W hy 
‘big’ data” and the related issue of the potential tradeoff 
between data size and data quality. To answer this 
question, he provided a very brief conceptualization of 
supervised machine learning using a project to identify 
spurious glucose results as an example.[27] In particular, 
he discussed the idea of overfitting. Overfitting occurs 
when a machine learning model fits to random patterns 
within a set of “training” data that do not generalize. 
Overfit models “mistake noise for a real pattern” and 
will perform better in classifying training data than an 
independent set of test data. Overfitting will tend to 
increase with the complexity of the model being fit and 
decrease with the size of the training data used to fit the 
model. Model complexity parallels degrees of freedom 
and thus models incorporating many parameters (fit to 
high-dimensional data) will tend to be complex and prone 
to overfitting. Because these are the types of models we 
may wish to fit using pathology data, we will need large 
datasets from large health systems and eventually, large 
inter-institutional data exchange networks.
Another consideration Dr. Baron discussed is the 
potential tradeoff between data size and data quality. 
Data quality may be limited by factors including 
completeness, accuracy, accessibility and structure. 
In the case of structure, there may be a real tradeoff 
between size and quality, because although unstructured 
data can be manually encoded to a more structured 
format, the resources required to do so are roughly 
proportional to the size of the dataset. Although 
high-quality, high-quantity data would be optimal from 
a data mining point of view, in some cases, it  is possible 
that a very large dataset may be useful even if relatively 
low quality. Google Flu Trends[28] is an example in which 
high-quality information (influenza trends) is derived 
from very high quantity but, in many regards, low 
quality data (unstructured flu-related Google internet 
searches).
Ramy Arnaout, MD, DPhil
Dr. Ramy Arnaout, Assistant Professor of Pathology and 
Associate Director of the Clinical Microbiology Laboratory 
at the Beth Israel Deaconess Medical Center (BIDMC) 
and faculty in Clinical Informatics at BIDMC and the 
Systems Biology PhD program at Harvard Medical School, 
discussed the landscape of inappropriate laboratory 
testing in medicine in his talk “Clinical Laboratory Data 
by the Numbers.” As pathologists look to update the 
specialty’s value proposition for the age of big data, a 
fitting question is how well clinicians interact with the 
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single largest source of data in pathology: Laboratory 
testing.
Dr. Arnaout pointed out that laboratory testing is the 
single highest-volume medical activity, with over six 
billion tests performed each year in the United States 
alone. He also noted that the prevailing narrative 
at hospitals in regard to laboratory testing is that 
unnecessary repeat testing is the crux of the problem and 
is bankrupting medicine. He then proceeded to describe 
results from a 15-year meta-analysis, in which his group 
reviewed over 1.5 million orders covering 46 of the 50 
most frequently ordered tests, that suggested that this 
narrative is categorically wrong. “Inappropriate laboratory 
utilization is widespread, but it’s not where we think,” 
he said. Understanding when and how inappropriate 
utilization occurs, he argued, gives pathologists a 
tremendous opportunity to reshape information flows 
to make this high volume medical activity better 
serve patients and clinicians. The data presented in 
Dr. Arnaout’s talk is available in a recent publication.[29]
Block 4 Presentations: Practical Consideration 
and Strategies to Br ing Big Picture Ideas to 
Implementable Endeavors
JiYeon Kim, MD, MPH
JiYeon Kim, Physician-in-Charge of Chemistry and 
Laboratory Informatics at the Regional Reference 
Laboratories of Southern California Permanente 
Medical Group, delivered a talk, “Lab Data and Patient 
Outcomes.” She began her talk by comparing the 
implications of evidence-based decision-making in 
medicine, such as treatment options based on lab data, 
to driver-less cars. She explained that Google’s tests with 
self-driven cars provide evidence that they are far safer 
than cars driven by the typical human driver. In fact, 
it should be noted that the Google car’s only reported 
collision to date was the fault of a human driver who 
rear-ended the car driven by the Google computer. 
However, people may be much more accepting of errors 
made by humans (from whom errors are expected) 
than by machines and may be willing to accept a more 
error-prone human performing a task over a less-error 
prone machine. Similarly, for laboratory clinical decision 
support, an algorithm providing clinical advice (or even 
an automated diagnosis or treatment) may be held to 
a much higher standard than would a person providing 
the same function. A consequence of this philosophy is 
that health care systems may choose not to implement 
decision support systems that fail to reach a standard of 
perfection for every patient, even when such algorithms 
could clearly improve diagnostic quality or safety for the 
population as a whole.
Dr. Kim also argued that laboratories should move 
beyond just presenting test results alone, as there are 
many instances where the lab data can be prone to 
over-interpretation, potentially leading to inappropriate 
treatment or adverse outcomes. For example, studies 
have shown some physicians order troponins on patients 
indiscriminately and then admit patients with low-level 
troponin elevations, even when there is no clinical basis 
to suspect cardiac ischemia. In some of these cases, the 
clinicians may be failing to interpret the troponins in a 
Bayesian context; given a very low pretest likelihood of 
cardiac ischemia, even a positive troponin result may 
likely be a false positive. Dr. Kim implies that laboratories 
could help improve this situation by taking a greater 
role in ensuring that troponins be ordered only when 
clinically indicated and that they be reported in a way 
that incorporates clinical context. Troponins are just one 
of many examples fitting this paradigm.
Another point made by Dr. Kim related to how 
laboratories have large quantities of structured data 
at their disposal; mining this data has the potential 
to better identify patterns that may inform and refine 
appropriate treatment. Finally, Dr. Kim argues that given 
the laboratory’s key role in diagnosing a wide-range of 
diseases, the laboratory needs to develop partnerships 
through the health care system and particularly with 
patients themselves. This may include expanding the 
provision of actionable information directly to patients.
Walter Henricks, MD
Walter Henricks, Medical Director of the Center 
for Pathology Informatics and Staff Pathologist at 
the Pathology and Laboratory Medicine Institute of 
the Cleveland Clinic, offered a number of practical 
considerations and decision support opportunities in his 
talk, “Pathology’s Role in Implementation of Laboratory 
Test Order Management in the EHR.” Many of the 
opportunities he described are not only possible in the 
present, but might also facilitate some of the longer term 
goals described in some of the other talks.
Dr. Henricks began by noting that many of the 
informatics and decision support challenges we face 
are “more than IT” and really involve “people” and 
“processes” as well. He next noted some of the strategies 
he and colleagues employ at the Cleveland Clinic within 
their Epic EHR and its CPOE capabilities. Among these 
are “hard stops” implemented in the CPOE systems to 
prevent clinicians from placing duplicate orders on the 
same day for certain laboratory tests; overriding these 
hard stops requires placing a call to the laboratory. “Soft 
stops” are a utilization tool related to hard stops, in which 
the ordering provider has the opportunity to override 
the alert and proceed with ordering the test. Because of 
initially uneven adoption of CPOE and the availability 
of process workarounds at community hospitals in its 
health system, Cleveland Clinic deployed soft stops as a 
lower risk and a more politically viable first step in such 
mixed-provider environments.
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Cleveland Clinic has also implemented decision support 
rules that restrict the ordering of certain complex and 
typically expensive genetic and genomic tests to clinicians 
who are “deemed users.” Deemed users mostly consist 
of specialists in the disorder(s) for which the test is 
appropriately used. Non-deemed users must get approval 
from the laboratory, medical genetics, or a deemed user 
prior to ordering. For requests referred to the laboratory, 
a laboratory-based genetics counselor assists in the review 
and a molecular genetic pathologist is the approver. 
In addition, the Cleveland Clinic further restricts use 
of these tests specifically on inpatients by allowing 
the test only if recommended by a medical genetics 
consultation. The CPOE system also displays guidance 
for pharmacogenomic testing and relevant previous 
pharmacogenomic results to providers when they order 
certain medications.
Because “people” and “governance” are key 
considerations in implementing these types of decision 
support, Dr. Henricks noted the importance of having 
a test utilization committee to determine the decision 
support rules and alert criteria used in the CPOE 
system. A pathologist chairs this committee, which has 
“multidisciplinary” membership including members of 
other clinical departments (all department heads are 
invited) and IT leadership. The committee provides 
recommendations to hospital leadership, including the 
Chief Executive Officer, Chief of Staff and Chief of 
Medical Operations for support and approval.
Anand Dighe, MD, PhD
Anand Dighe, Associate Pathologist and Director of 
the Core Laboratory in the Department of Pathology 
at the MGH and Associate Professor of Pathology 
at Harvard Medical School, delivered the final talk 
of the symposium, “Barriers and Opportunities for 
Pathologist-Driven Decision Support.” In it he argued 
that expectations for clinical laboratories are too low; 
the current bar which simply requires laboratories to 
report basic observations and data needs to be raised. 
Laboratories should increasingly be looked upon help 
guide test selection and provide diagnostic information, 
rather than simple observations. W hile meeting these 
higher expectations could drastically enhance the value of 
laboratory testing, there are numerous barriers to doing 
so. Given the sheer volume of laboratory tests, manual 
pathologist involvement must be limited to select cases; 
in most instances, electronic decision support systems 
need to be developed and deployed to provide this 
enhanced diagnostic value.
Dr. Dighe specifically described six barriers along 
with possible solutions. The first of these barriers was 
“Someone else is already doing it.” By this he meant that 
at many institutions, the CPOE and other electronic 
systems are controlled by non-pathologists; however, 
pathologists need to be involved in or ideally control the 
clinical content of the CPOE system for laboratory tests 
to enable them to manage test utilization and appropriate 
test selection. A related barrier is “we (pathologists) don’t 
have the tools to do the job.” With this second barrier, 
Dr. Dighe was pointing out that even when pathologists 
want to be involved in the content of a CPOE system 
and have the administrative authority to do so, their 
ability may be technically limited by a need to request 
IT resources to make CPOE updates. One solution is for 
pathologists to develop middleware applications, such as 
the MGH Path Connect System,[30] that allow them to 
update the clinical content of the CPOE systems without 
involvement of IT staff.
The third barrier discussed is that most laboratories and 
health systems now use primarily commercially developed 
systems that often leave limited opportunities for 
customization. Nonetheless, Dr. Dighe argued that many 
of these systems offer “untapped capabilities” meaning 
that some apparent limitations may be in a health 
system’s understanding or application of its systems and 
not in the systems themselves. In addition, when a new 
system is being selected or deployed, Dr. Dighe argued 
that it is imperative that pathologists be involved early 
and throughout the process. The fourth barrier Dr. Dighe 
mentioned is “W hy can’t our providers just use the 
system properly?” The key here is that laboratories should 
not assume that clinicians will properly use whatever 
systems they are initially given. It is important to collect 
data on how providers interact with the system to make 
adjustments and provide additional user education as 
indicated.
The fifth barrier is “I can’t get useful reports out of the 
system.” By this, Dr. Dighe is cautioning against being 
reliant on central hospital or enterprise IT services to 
provide a report every time important data is needed from 
the LIS or CPOE systems. It is important for pathologists 
to have a way to access this data in real time to make 
operational improvements and optimally fulfill their 
responsibilities. Having to wait in queues (potentially 
months long) to get needed data can severely impair 
laboratory operations. One solution is for pathologists to 
create data marts that store mirrors of data in the LIS 
and CPOE systems that pathologists can query as needed 
to generate key reports and metrics.
The sixth barrier is the historic perception in some 
laboratories that “Once the result is sent to the EHR, 
I’m done.” In contrast to this view, Dr. Dighe argued 
that laboratories could greatly enhance value by taking 
steps to ensure that “actionable” laboratory results are 
properly acted upon. “Dropped balls” (laboratory results 
not properly follow-up or acted upon) are of particular 
concern with information that is time-sensitive, but 
is not critical, since critical results are directly called 
[Downloaded free from http://www.jpathinformatics.org on Friday, September 30, 2016, IP: 128.252.11.235]
J Pathol Inform 2014, 1:2 http://www.jpathinformatics.org/content/5/1/2
to a responsible person. Results viewers that require 
responsible clinicians to acknowledge actionable results 
with processes to follow-up if acknowledgment does 
not occur within a specified period may be useful. 
Laboratories need to consider processes and strategies 
to monitor and avoid result communication and action 
failures.
DISCUSSION
A number of recurrent themes emerged from the 
symposium. Perhaps the most pervasive of these related to 
the dichotomy between data and diagnostic information[2] 
with regard to laboratory testing. In particular, laboratories 
currently produce primarily observational data and leave 
it to clinicians to integrate these data and convert data 
into true diagnostic information. However, the human 
brain is not well-equipped to interpret multidimensional 
data,[17,18] and laboratory and clinical data typically 
exist as large numbers of discrete observations. This 
highlights the need for computational systems to convert 
laboratory data to information, effectively reducing the 
dimensionality of the information that clinicians must 
process.
Likewise, there are differences between human talents 
and computer abilities; well-designed symbioses between 
humans and computers may ultimately optimize 
diagnosis. Furthermore, unsupervised statistical analysis 
of data alone may not be sufficient and we may instead 
need to constrain our analysis though use of mechanistic 
physiologic models. We will also need to incorporate 
human intuition and domain expertise into our models.
Another facet that emerged related to the often complex 
relationship between data and the information that can 
derived from it.[26,27] For example, MAAAs use large sets 
of laboratory values to provide key information that raw 
data alone could not. A corollary to this idea is that much 
of the laboratory data currently produced is not fully 
converted to information. A key strategy to improving 
laboratory diagnosis is to better utilize available data. 
However, a challenge will involve identifying patterns 
in data without overfitting, or in other words, clearly 
discriminating “signal from noise”. Another major theme 
from the symposium involved the unique challenges 
posed by emerging diagnostic technologies and in 
particular, next generation sequencing. In genomics, 
the separation between data and information is far 
greater than in most traditional areas of diagnostic 
testing. W hile with basic laboratory testing, considerable 
information can be manually extracted from the relatively 
unprocessed data, this is impossible within the context 
of next generation sequencing. Raw sequence reads 
are useless in diagnosis without further computational 
processing, alignment, base calling and variant-calling 
with additional and potentially extensive clinical and 
familial correlation for variants that are not already well 
defined. Furthermore, interpretation of next generation 
sequencing data requires a computer-usable knowledge 
base derived from the literature and prior experience 
and systems to apply this knowledge to help automate 
interpretation. Without this, manual review of identified 
variants would be cost prohibitive. Other challenges 
with regard to genomics include the consideration that 
much of the data generated is of yet to be determined 
significance and that the knowledge base is in constant 
flux. As with other areas, guiding clinicians as to the 
appropriate action to take in response to genomic results 
is critical.
The utility of automating various aspects of information 
processing was another recurrent theme. For example, a 
computational infrastructure may eventually help transform 
the fields of pathology and laboratory medicine into 
central diagnostic specialties, providing integrative reports 
that clearly define precise diagnoses with clear therapeutic 
information in many cases. Likewise, laboratory data 
could potentially be used to provide overarching objective 
evaluations of pathologist and trainee performance as well 
as a comprehensive understanding of the value and utility 
of various health care services.
A final theme that emerged related to how many of 
the barriers to bringing decision support toward reality 
are really personnel, political, infrastructural and 
administrative challenges rather than technological 
limitations. For example, training and educating 
pathologists is a key measure in driving this field forward. 
Likewise, while superficially a technological consideration, 
a key component to developing the “professional LIS” 
may lay in building co-development relationships 
between pathologists and LIS vendors. Moreover, the 
functionality of information systems may be limited by 
the knowledge base of the people using them. Likewise, 
strong governance and organizational structures are keys 
to the success of decision support efforts at large medical 
centers.
Both patients and clinicians stand to benefit from the 
greater diagnostic precision, optimized test utilization, 
improved efficiency and reduced costs that may stem 
from enhanced pathology decision support. For example, 
pathology decision support could benefit patients through 
more rapid or precise diagnosis, allowing them to receive 
treatments that are more “personalized,” timely and 
clinically optimal. This should in turn improve outcomes, 
reduce side-effects from ineffective treatments and reduce 
patients’ cost of care. Likewise, physicians may benefit 
through improved efficiency, reduced risk of error and 
enhanced diagnostic capacity. The improved efficiency 
may also provide clinicians with the opportunity to spend 
more time interacting with patients and performing other 
rewarding clinical activities.
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However, the potential benefits of pathology decision 
support are not limited to direct patient care. Rather, this 
emerging field may also offer new research opportunities 
and improve the economics of pathology services. For 
example, expanded decision support should generate 
novel clinical research questions. In particular, clinical 
research will be needed to investigate the optimal 
strategies for management of clinical conditions in 
the setting of increased diagnostic precision. Likewise, 
health systems research will be needed to study the 
effects of the decision support systems themselves. 
Similarly, the improved ability to convert raw genomic 
data into clinically actionable information will facilitate 
translational genomic research. Basic science researchers 
may be called upon to investigate the biologic or 
physiologic mechanisms underlying newly identified 
patterns within clinical data. Finally, by enhancing the 
value of laboratory services and helping to demonstrate 
the contribution that laboratory testing provides 
to patient care, electronic decision support systems 
could improve the economics of pathology. Indeed, 
as accountable care organizations expand and provide 
health systems with a single limited pool of resources,[16] 
it may be particularly incumbent upon pathologists to 
demonstrate the value of their services.
Overall, the symposium illustrated that, while pathology 
decision support is a field still in its infancy, it is a field 
with tremendous opportunity and potential that is moving 
quickly. There is a clear need for inter-institutional 
collaboration to solve the technical, infrastructural and data 
acquisition challenges and to support LIS and EHR vendors 
in developing systems that can support emerging decision 
support strategies. We look forward to holding a follow-up 
symposium on this topic to discuss interim progress.
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